Literature DB >> 24347277

Replication-defective HSV-1 effectively targets trigeminal ganglion and inhibits viral pathopoiesis by mediating interferon gamma expression in SH-SY5Y cells.

Kun Xu1, Xian-Ning Liu, Hong-Bing Zhang, Na An, Yao Wang, Zhi-Chao Zhang, Ya-Ni Wang.   

Abstract

It has been widely believed that recurrence of herpes simplex keratitis (HSK) is due to the reactivation of herpes simplex virus type 1 (HSV-1) from latent sites in trigeminal ganglion (TG). However, there are also not effective vectors which could target TG for therapy. Replication-defective HSV-1 vector (rdHSV-IFNγ) was established by calcium phosphate co-transfection of complementing cells. We firstly infected rdHSV-IFNγ to SH-SY5Y, and detected IFNγ expression by western blot, evaluated 50 % cellular cytotoxicity (CC(50)) by ELISA. Antiviral activity of rdHSV-IFNγ was examined by immunofluorescence and antiviral concentration of 50 % effectiveness (EC(50)) assay. The rdHSV-IFNγ vector was immunized to Wistar rats to observe targeting function to TG. Kaplan-Meier survival analysis was utilized to assess security of rdHSV-IFNγ. RT-PCR and immunohistochemistry assay were employed to detect rdHSV-IFNγ localization in TG. Western blot was employed to detect IFNγ expression. rdHSV-IFNγ was successfully established, and performed an effective antiviral activity and higher security in SH-SY5Y. There were no significant differences of survival and corneal infection rate of rdHSV-IFNγ immunized rats among groups (P > 0.05). RT-PCR and immunohistochemistry indicated that expression of glycoprotein D (gD) in TG could target TG and decreased following with times post immunization. Furthermore, IFNγ was expressed effectively in TG tissues. Our findings indicated that established rdHSV-IFNγ vector effectively transported therapeutic gene into TG tissues. The administration of replication-defective vector carrying therapeutic genes may become a promising tool in inhibition or reoccurrence of HSK in clinical.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24347277     DOI: 10.1007/s12031-013-0199-x

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  24 in total

1.  Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo.

Authors:  C E Lilley; F Groutsi; Z Han; J A Palmer; P N Anderson; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  A procedure to deliver herpes simplex virus to the murine trigeminal ganglion.

Authors:  John L Whitehead; Peter T Ohara; Andrew N Tauscher; Jennifer H LaVail
Journal:  Brain Res Brain Res Protoc       Date:  2003-08

3.  A new approach with less damage: intranasal delivery of tetracycline-inducible replication-defective herpes simplex virus type-1 vector to brain.

Authors:  Y Jiang; N Wei; J Zhu; D Zhai; L Wu; M Chen; G Xu; X Liu
Journal:  Neuroscience       Date:  2011-11-10       Impact factor: 3.590

Review 4.  Gene therapy for the treatment of chronic peripheral nervous system pain.

Authors:  William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

Review 5.  Herpes simplex virus epidemiology and ocular importance.

Authors:  T J Liesegang
Journal:  Cornea       Date:  2001-01       Impact factor: 2.651

6.  Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli beta-galactosidase.

Authors:  A I Geller; A Freese
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

7.  Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.

Authors:  Sita Awasthi; John M Lubinski; Harvey M Friedman
Journal:  Vaccine       Date:  2009-09-15       Impact factor: 3.641

8.  A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection.

Authors:  N Goel; Q Rong; D Zimmerman; K S Rosenthal
Journal:  Vaccine       Date:  2003-10-01       Impact factor: 3.641

9.  Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs.

Authors:  Debra C Quenelle; Deborah J Collins; Terri L Rice; Mark N Prichard; Dante J Marciani; Earl R Kern
Journal:  Antiviral Res       Date:  2008-06-23       Impact factor: 5.970

Review 10.  Type I interferon and lymphangiogenesis in the HSV-1 infected cornea - are they beneficial to the host?

Authors:  Katie Bryant-Hudson; Christopher D Conrady; Daniel J J Carr
Journal:  Prog Retin Eye Res       Date:  2013-07-19       Impact factor: 21.198

View more
  7 in total

1.  Downregulation of Pygopus 2 inhibits vascular mimicry in glioma U251 cells by suppressing the canonical Wnt signaling pathway.

Authors:  Haidong Wang; Jianhua Fu; Dianshuang Xu; Weiwei Xu; Shiyong Wang; Liu Zhang; Yongsheng Xiang
Journal:  Oncol Lett       Date:  2015-11-13       Impact factor: 2.967

2.  Human interleukin-10 gene inhibits acute rejection by triggering apoptosis in allograft vascular transplantation.

Authors:  Haibo Liu; Shunzhang Yang; Xuejun Sun; Tianbao Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  Differentiation of the SH-SY5Y Human Neuroblastoma Cell Line.

Authors:  Mackenzie M Shipley; Colleen A Mangold; Moriah L Szpara
Journal:  J Vis Exp       Date:  2016-02-17       Impact factor: 1.355

4.  Preliminary screening of differentially expressed genes involved in methyl-CpG-binding protein 2 gene-mediated proliferation in human osteosarcoma cells.

Authors:  Gang Meng; Yi Li; YangFan Lv; Huanzi Dai; Xi Zhang; Qiao-Nan Guo
Journal:  Tumour Biol       Date:  2015-01-23

5.  Differentiated Human SH-SY5Y Cells Provide a Reductionist Model of Herpes Simplex Virus 1 Neurotropism.

Authors:  Mackenzie M Shipley; Colleen A Mangold; Chad V Kuny; Moriah L Szpara
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

6.  Establishment of a novel therapeutic vector targeting the trigeminal ganglion in rats.

Authors:  Kun Xu; Shi-Yin Pan; Jin-Xin Song; Xian-Ning Liu; Na An; Xuan Zheng
Journal:  Drug Des Devel Ther       Date:  2016-02-04       Impact factor: 4.162

7.  Association of Electroencephalography (EEG) Power Spectra with Corneal Nerve Fiber Injury in Retinoblastoma Patients.

Authors:  Jianliang Liu; Juanjuan Sun; Yumei Diao; Aijun Deng
Journal:  Med Sci Monit       Date:  2016-09-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.